The Omicron SARS-CoV-2 variant is responsible for a major wave of COVID-19, with record case counts reflecting high transmissibility and escape from prior immunity. Defining the time course of Omicron viral proliferation and clearance is crucial to inform isolation protocols aiming to minimize disease spread.
Tags: COVID-19, Omicron, SARS-CoV-2, viral infection
The SARS-CoV-2 B.1.1.529 (Omicron) variant contains 15 mutations of the receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies requires immediate investigation.
Tags: ACE2 protein, SARS-CoV-2, Spike Protein
Reference: Epidemiological characterization of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021
By 9 December 2021, 785 SARS-CoV-2 Omicron variant cases have been identified in Denmark. Most cases were fully (76%) or booster-vaccinated (7.1%); 34 (4.3%) had a previous SARS-CoV-2 infection. The majority of cases with available information reported symptoms (509/666; 76%) and most were infected in Denmark (588/644; 91%).
Tags: COVID-19, Denmark, Epidemiology, Omicron, SARS-CoV-2
Characteristics and treatment of Omicron variant of COVID-19.
Tags: COVID-19, Omicron, SARS-CoV-2
Jorge R Miranda-Massari, Alondra P Toro, Doris Loh, Jose R Rodriguez, Raul Morales Borges, Victor Marcial-Vega, Jose Olalde, Miguel J Berdiel, Neil H Riordan, Juan Manuel Martinez, Armando Gil, Michael J Gonzalez PMID: 34947872 PMCID: PMC8708699 DOI: 10.3390/life11121341 AbstractCurrently available anti-viral drugs may be useful in reducing the viral load but are not providing the [...]
Tags: Ascorbic Acid, COVID-19, SARS-CoV-2
Reference: Retrospective cohort study of Ivermectin as a SARS-CoV-2 pre-exposure prophylaxis method in Healthcare Workers
Ivermectin is a drug that has been shown to be active against coronavirus disease 19 (COVID-19) in previous studies. Healthcare personnel are highly exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Therefore, we decided to offer them ivermectin as a pre-exposure prophylaxis (PrEP) method.
Tags: ivermectin, SARS-CoV-2
Reference: Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 delta variant
The first local transmission of the SARS-CoV-2 Delta variant in mainland China ... suggesting potentially faster viral replication and greater infectiousness of Delta during early infection
Tags: Delta variant, SARS-CoV-2
Reference: Possible therapeutic effects of adjuvant Quercetin supplementation against early stage COVID-19 infection:A prospective, randomized, controlled, and open-label study
Quercetin, a well-known naturally occurring polyphenol, has recently been shown by molecular docking, in vitro and in vivo studies to be a possible anti-COVID-19 candidate. Quercetin has strong antioxidant, anti-inflammatory, immunomodulatory, and antiviral properties, and it is characterized by a very high safety profile, exerted in animals and in humans. Like most other polyphenols, quercetin shows a very low rate of oral absorption and its clinical use is considered by most of modest utility. Quercetin in a delivery-food grade system with sunflower phospholipids (Quercetin Phytosome®, QP) increases its oral absorption up to 20-fold.
Reference: Early empirical assessment of the N501Y mutant strains of SARSCoV-2 in the United Kingdom, October to November 2020
Two new SARS-CoV-2 lineages with the N501Y mutation in the receptor-binding domain of the spike protein spread rapidly in the United Kingdom. We estimated that the earlier 501Y lineage without amino acid deletion Δ69/Δ70, circulating mainly between early September and mid-November, was 10% (6–13%) more transmissible than the 501N lineage, and the 501Y lineage with amino acid deletion Δ69/Δ70, circulating since late September, was 75% (70–80%) more transmissible than the 501N lineage.
Reference: A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin
Martin D. Hellwig a, Anabela Maia b https://doi.org/10.1016/j.ijantimicag.2020.106248 Abstract As COVID-19 (coronavirus disease 2019) continues to rapidly spread throughout the world, the incidence varies greatly among different countries. These differences raise the question whether nations with a lower incidence share any medical commonalities that could be used not only to explain that lower incidence [...]